Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 9/20 | 0.75 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.75 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.75 |
| ▸ | PTGES | O14684 | 1/20 | 0.75 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.75 |
| ▸ | POLL | Q9UGP5 | 7/20 | 0.47 |
| ▸ | STAT1 | P42224 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 3/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Garcinol SCHEMBL29395703 | 1.00 | EP300 (0.75) | EP300HDAC11KAT2BPTGESHDAC8 | |
| Guttiferone F SCHEMBL31345886 | 1.00 | EP300 (0.75) | EP300HDAC11KAT2BPTGESHDAC8 | |
| Guttiferone F SCHEMBL19565392 | 1.00 | EP300 (0.75) | EP300HDAC11KAT2BPTGESHDAC8 | |
| Guttiferone F SCHEMBL23815758 | 1.00 | EP300 (0.75) | EP300HDAC11KAT2BPTGESHDAC8 | |
| Guttiferone F SCHEMBL23815733 | 1.00 | EP300 (0.75) | EP300HDAC11KAT2BPTGESHDAC8 | |
| Guttiferone F SCHEMBL23607580 | 1.00 | EP300 (0.75) | EP300HDAC11KAT2BPTGESHDAC8 | |
| Guttiferone F SCHEMBL25049796 | 1.00 | EP300 (0.75) | EP300HDAC11KAT2BPTGESHDAC8 | |
| Guttiferone F SCHEMBL23815760 | 1.00 | EP300 (0.75) | EP300HDAC11KAT2BPTGESHDAC8 | |
| Garcinol SCHEMBL294532 | 1.00 | EP300 (0.75) | EP300HDAC11KAT2BPTGESHDAC8 | |
| Xanthochymol SCHEMBL294395 | 0.92 | EP300 (0.63) | EP300HDAC11KAT2BPTGESHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025024478-A1 | COMPOSITIONS FOR THE MODULATION OF TASTE | IXORA SCIENTIFIC INC. (US) | 2025-01-30 | — | — | WO | claimed |
| CN-104940177-A | Medical application of guttiferone F | UNIV SHANGHAI OF T C M | 2015-09-30 | — | — | CN | claimed |
| US-20150025155-A1 | ANTI-PROSTATE CANCER COMPOUND AND METHOD OF USE THEREOF | HONG KONG BAPTIST UNIVERSITY (HK) | 2015-01-22 | — | — | US | claimed |
| WO-2025024478-A1 | COMPOSITIONS FOR THE MODULATION OF TASTE | IXORA SCIENTIFIC INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| CN-104940177-B | Medical application of vine flavone F | 上海中医药大学 | 2020-06-26 | — | — | CN | disclosed |
| US-20150025155-A1 | ANTI-PROSTATE CANCER COMPOUND AND METHOD OF USE THEREOF | HONG KONG BAPTIST UNIVERSITY (HK) | 2015-01-22 | — | — | US | disclosed |
| US-20150025155-A1 | ANTI-PROSTATE CANCER COMPOUND AND METHOD OF USE THEREOF | HONG KONG BAPTIST UNIVERSITY (HK) | 2015-01-22 | — | — | US | disclosed |
| US-20150025155-A1 | ANTI-PROSTATE CANCER COMPOUND AND METHOD OF USE THEREOF | HONG KONG BAPTIST UNIVERSITY (HK) | 2015-01-22 | — | — | US | disclosed |
| CN-102212507-A | Hypericum sampsonii hance benzophenone synthase and coding genes thereof | INST BOTANY CAS | 2011-10-12 | — | — | CN | disclosed |
| EP-1529025-B1 | POLYISOPRENYLBENZOPHENONE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-07-16 | — | — | EP | disclosed |
| US-6956061-B2 | Polyisoprenylbenzophenone derivatives, processes for their preparation and use thereof | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-10-18 | — | — | US | disclosed |
| EP-1529025-A1 | POLYISOPRENYLBENZOPHENONE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF | Aventis Pharma Deutschland GmbH (DE) | 2005-05-11 | — | — | EP | disclosed |
| US-20040082662-A1 | Polyisoprenylbenzophenone derivatives, processes for their preparation and use thereof | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-04-29 | — | — | US | disclosed |
| WO-2004014831-A1 | POLYISOPRENYLBENZOPHENONE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | EP300 917/4885HDAC11 1566/4885KAT2B 2513/4885 |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | EP300 917/4885HDAC11 1566/4885KAT2B 2513/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | EP300 1842/4885HDAC11 1735/4885KAT2B 645/4885 |
| US-20150025155-A1 | ANTI-PROSTATE CANCER COMPOUND AND METHOD OF USE THEREOF | KLK3, ACP3, CASP3 | EP300 602/4885HDAC11 564/4885KAT2B 720/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | EP300 642/4885HDAC11 861/4885KAT2B 735/4885 |
| US-20040082662-A1 | Polyisoprenylbenzophenone derivatives, processes for their preparation and use thereof | GGPS1, PGGT1B, GNPAT | EP300 579/4885HDAC11 2663/4885KAT2B 2710/4885 |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | EP300 447/4885HDAC11 798/4885KAT2B 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.